This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health?
by Indrajit Bandyopadhyay
DOCS and IRTC are redefining digital health with AI, but only one is winning big with investors in 2025's market surge.
IRTCNegative Net Change DOCSPositive Net Change
medical medical-devices
GE HealthCare Stock Slips Despite the Launch of bkActiv S Series
by Zacks Equity Research
GEHC expands its bkPortfolio with the AI-powered bkActiv S Series to advance ultrasound-guided procedures.
ANGOPositive Net Change CVSPositive Net Change ITGRNegative Net Change GEHCNegative Net Change
medical medical-devices
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance.
ARAYPositive Net Change ANGOPositive Net Change CVSPositive Net Change ITGRNegative Net Change
medical medical-devices
ISRG vs BSX: Which Medical Device Stock Has More Room to Run?
by Indrajit Bandyopadhyay
Boston Scientific offers steady growth with broader exposure, while Intuitive Surgical leads in robotics but faces margin and tariff headwinds.
BSXPositive Net Change ISRGPositive Net Change
medical medical-devices
Labcorp Stock Climbs 25.6% This Year: What's Driving the Surge?
by Zacks Equity Research
LH stock surges 25.6% this year, powered by specialty testing expansion, key acquisitions and solid financials.
LHPositive Net Change CORPositive Net Change PAHCPositive Net Change HIMSPositive Net Change
medical medical-devices
Exploring CVS' Health Services Segment: A Key Growth Engine for 2025?
by Moumi Mondal
CVS' Health Services segment posts $43B in revenues as specialty pharmacy and Caremark deals drive 2025 growth prospects.
NVONegative Net Change HUMNegative Net Change CINegative Net Change CVSPositive Net Change
medical medical-devices
VEEV Stock May Gain on the Launch of China Campaign Manager for Pharma
by Zacks Equity Research
Veeva Systems launches China Campaign Manager to boost pharma engagement with localized, compliant CRM-driven solutions.
ANGOPositive Net Change CVSPositive Net Change VEEVPositive Net Change ITGRNegative Net Change
medical medical-devices
After Golden Cross, Diversified Healthcare (DHC)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
DHCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Box (BOX) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
BOXPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ISRG's Minimally Invasive Ecosystem Powers Surgical Precision
by Indrajit Bandyopadhyay
ISRG's robotic platforms, led by da Vinci and Ion, are transforming surgical precision and driving strong stock gains.
JNJPositive Net Change ISRGPositive Net Change EWNegative Net Change
medical medical-devices
DGX Stock Up on New Blood Test Development Deal With MD Anderson
by Zacks Equity Research
DGX stock rises on a new partnership with MD Anderson to develop a blood test targeting multiple cancer risks.
DGXPositive Net Change CORPositive Net Change PAHCPositive Net Change HIMSPositive Net Change
medical medical-devices
4 Stocks With Solid Net Profit Margins to Boost Portfolio Returns
by Anirudha Bhagat
Here we present four stocks, GLDD, TILE, CPRX and STRL, with solid net profit margins that can contribute to making a strong portfolio.
STRLPositive Net Change GLDDPositive Net Change CPRXPositive Net Change TILEPositive Net Change
construction industrial-products medical medical-devices pharmaceuticals transportation
GEHC Stock Declines Despite Expansion in Precision Care Capabilities
by Zacks Equity Research
GE HealthCare integrates proprietary algorithms into MIM Encore to advance digital imaging and workflow precision.
CORPositive Net Change ITGRNegative Net Change HIMSPositive Net Change GEHCNegative Net Change
medical medical-devices
INBS Stock May Rise on SMARTOX Partnership Expanding Forensic Reach
by Zacks Equity Research
Intelligent Bio Solutions collaborates with SMARTOX to expand U.S. forensic reach, boosting its drug test tech and eyeing FDA clearance for growth.
ANGOPositive Net Change CVSPositive Net Change ITGRNegative Net Change INBSNegative Net Change
medical medical-devices
3 Medical Services Stocks Capitalizing on the Healthcare AI Boom
by Urmimala Biswas
CVS, BTSG and WGS are three medical services stocks tapping into AI and tech-driven care to boost diagnostics, cut costs and drive growth in 2025.
CVSPositive Net Change WGSPositive Net Change BTSGPositive Net Change
artificial-intelligence hospitals medical medical-devices
Should You Buy Credo Technology Group Holding Ltd. (CRDO) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CRDOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Amarin (AMRN) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
AMRNPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Alpha Cognition Inc. (ACOG) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ACOGNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?
by Moumi Mondal
HOLX lifts margins despite tariffs and weak China sales, leaning on diagnostics strength and high-margin buys.
HOLXNegative Net Change BIOPositive Net Change GEHCNegative Net Change
medical medical-devices
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?
by Zacks Equity Research
MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.
MYGNNegative Net Change CORPositive Net Change PAHCPositive Net Change HIMSPositive Net Change
medical medical-devices
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
by Zacks Equity Research
OPK's growth hinges on RAYALDEE and key partnerships, but rising competition and reliance on one drug pose risks.
ANGOPositive Net Change CVSPositive Net Change OPKPositive Net Change ITGRNegative Net Change
medical medical-devices
Should You Add QIAGEN Stock to Your Portfolio for Now?
by Zacks Equity Research
QGEN rides on test menu growth, strategic partnerships, and strong solvency, despite macro and market headwinds.
QGENNegative Net Change CORPositive Net Change PAHCPositive Net Change HIMSPositive Net Change
medical medical-devices
Tempus AI's Expanding Ties Boost Novel R&D Efforts and Market Reach
by Moumi Mondal
TEM expands major partnerships with AZN, ILMN, and PSNL, fueling AI-driven R&D and widening its precision medicine reach.
AZNNegative Net Change ILMNPositive Net Change PSNLNegative Net Change TEMPositive Net Change
medical medical-devices
Thermo Fisher Stock Hurt by Macroeconomic Woes, Tough Competition
by Zacks Equity Research
TMO grapples with macro pressures, rising expenses and fierce competition, but bets on acquisitions to fuel recovery.
TMOPositive Net Change PBHNegative Net Change PAHCPositive Net Change INSPNegative Net Change
medical medical-devices
Five Below (FIVE) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
FIVEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines